Last reviewed · How we verify
NCT05498168
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
trial testing ratio of predicted neoantigens in Esophageal Cancer in 50 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | University Medical Center Ho Chi Minh City (UMC) |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 September 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- ratio of predicted neoantigens
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Neoantigen — all drugs for Neoantigen →
Sponsor
University Medical Center Ho Chi Minh City (UMC)
Who can join
Adults 15 to 90, any sex, with Esophageal Cancer or Neoantigen. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05498168
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ratio of predicted neoantigens
Trials testing the same drug.
- NCT05498194 — Computational Prediction and Experimental Validation of Gastric Cancer Associated Neoantigens · unknown
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other University Medical Center Ho Chi Minh City (UMC) trials
Trials by the same sponsor.
- NCT06768463 — Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer · NA · recruiting
- NCT06595290 — Vietnamese Rapid Acceleration Protocol for Intensifying Drug Therapy in Heart Failure With Reduced Ejection Fraction · NA · recruiting
- NCT07000383 — Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome · NA · recruiting
- NCT07100769 — Application of Real-time Ultrasound Guidance in Thoracic Epidural Catheter Placement · NA · recruiting
- NCT06648720 — Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05498168 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Ho Chi Minh City (UMC)
- Last refreshed: 11 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498168.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing